Boston Scientific Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael F. Mahoney
- Full Time Employees
- 59,000
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 300 Boston Scientific Way Marlborough MA United States of America 01752-1234
- IPO Date
- May 19, 1992
- CIK
- 0000885725
- Website
- bostonscientific.com
- Similar Companies
- Business
- Boston Scientific Corporation (NYSE: BSX) develops, manufactures and markets innovative medical devices for a wide range of interventional medical specialties worldwide. The company operates through two primary reportable segments, MedSurg and Cardiovascular, encompassing eight core businesses: Cardiac Rhythm Management, Electrophysiology, Endoscopy, Interventional Cardiology Therapies, Neuromodulation, Peripheral Interventions, Urology and WATCHMAN; its product portfolio includes pacemakers, defibrillators (S-ICD, ICD), CRT-P devices, deep brain stimulation systems, radiofrequency ablation systems for pain management, renal denervation technologies, direct visualization systems, embolic protection and embolization devices, FFR and IVUS systems, guidewires, imaging systems, intragastric balloons, lasers for BPH and lithotripsy, plaque modification tools, retrieval devices, RF ablation systems, hemostasis needles, hepatopancreatobiliary stents, hydrogel spacers, infection prevention products, pelvic floor reconstruction devices, penile prostheses and single-use imaging systems. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company maintains commercial operations in over 127 countries, including the U.S., Europe, Middle East and Africa, Asia-Pacific, Latin America and Canada, serving approximately 44 million patients annually through healthcare professionals in fields such as interventional cardiology, endoscopy, neuromodulation, peripheral interventions and urology. In recent developments, Boston Scientific has pursued an aggressive acquisition strategy, including agreements to acquire Bolt Medical for up to $664 million to enhance its intravascular lithotripsy offerings for coronary and peripheral artery disease (expected close in first half of 2025), SoniVie Ltd. for up to $600 million to advance therapeutic intravascular ultrasound for renal denervation in hypertension treatment (expected close in first half of 2025), Elutia's BioEnvelope division to reduce complications in cardiac rhythm management devices, Anrei Medical for $182 million to bolster endoscopy solutions, Intera Oncology for interventional oncology in liver metastases, and Cortex; the company also completed its $3.7 billion acquisition of Axonics in November 2024 and received $2.6 million in state funding for a 52,000-square-foot manufacturing expansion at its Maple Grove, Minnesota campus to support WATCHMAN product growth, alongside launching approximately 100 new products in 2024.
Boston Scientific: A Deep Dive Into The Headwinds And Why I See A Recovery Ahead
Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet
B. Riley Wealth Advisors Inc. Trims Holdings in Boston Scientific Corporation $BSX
Boston Scientific Corporation $BSX Shares Sold by E. Ohman J or Asset Management AB
Boston Scientific: The $5.4 Billion Quarter Tells Me The Sell-Off Is Overdone
Boston Scientific Director Habiger Buys $100k of Shares Amid 54% Decline. What Does This Mean for BSX in 2026?
Boston Scientific CEO Mahoney Buys More Than 200k Shares for $10 Million. What Does This Mean for Investors in 2026?
Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results
Boston Scientific's 2026 Guidance Cut Puts Its Recovery to the Test
Should Investors Buy Boston Scientific Stock Despite Near-Term Risks?
Bear of the Day: Boston Scientific (BSX)
First National Bank of Mount Dora Trust Investment Services Takes Position in Boston Scientific Corporation $BSX
Here Are Friday’s Top Wall Street Analyst Research Calls: Blackstone Mortgage, Boston Scientific, Edison International, Ford, GoDaddy, International Paper, Roblox, Saia, and More
Bank of America Corp DE Has $1.43 Billion Stock Holdings in Boston Scientific Corporation $BSX
Penumbra, Inc. Reports Second Quarter 2026 Financial Results
BSX Q2 Earnings Call Highlights WATCHMAN and EP Pressure
Boston Scientific: Attempting The 2027 Reset
Boston Scientific Q2 Earnings Call Highlights
Boston Scientific Corp (BSX) Q2 2026 Earnings Call Highlights: Strong Growth in Interventional Cardiology and Neuromodulation
Boston Scientific beats second quarter expectations, raises full-year outlook